0538T Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)

Name of the Procedure:

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy; Preparation of Blood-Derived T Lymphocytes for Transportation (Cryopreservation and Storage)

Summary

The process involves collecting T lymphocytes (a type of white blood cell) from a patient's blood and preparing them for transportation by freezing (cryopreservation) and storing them until needed for CAR-T therapy.

Purpose

This preparation is essential for CAR-T therapy, a treatment aimed at some types of cancer. The goal is to modify the patient's T cells to target and destroy cancer cells.

Indications

• Certain types of cancer, such as B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL)
• Patients who have not responded to other treatments or have relapsed

Preparation

• Patients may need to undergo blood tests and imaging studies to assess overall health and eligibility.
• No special preparation like fasting is typically required for the initial blood collection.

Procedure Description

1. Blood Collection: Blood is drawn from the patient, usually through a vein in the arm.
2. T-Cell Isolation: T lymphocytes are separated from the rest of the blood components.
3. Cryopreservation: The isolated T cells are mixed with a cryoprotectant to prevent cell damage and then gradually frozen.
4. Storage: The frozen cells are stored in a controlled environment until they are ready to be transported to the lab for modification and expansion.

Duration

The preparation process, including blood collection and cryopreservation, typically takes a few hours.

Setting

The procedure is usually performed in a hospital or specialized outpatient clinic.

Personnel

• Hematologists or oncologists
• Specialized nurses or technicians
• Lab personnel handling cryopreservation and storage

Risks and Complications

• Risk of infection from the blood draw
• Potential allergic reaction to cryoprotectants (very rare)
• Cells may not survive the freezing and thawing process (rare but possible)

Benefits

• Enables the subsequent CAR-T therapy, which can provide significant improvement or remission in certain cancers.
• The cryopreservation process allows flexibility in timing for the therapy.

Recovery

• Minimal recovery time is needed after the blood draw.
• Patients may resume normal activities shortly after the procedure.

Alternatives

• Other forms of immunotherapy or targeted therapy
• Bone marrow or stem cell transplantation
• Chemotherapy or radiation therapy Pros and cons of each alternative should be discussed with healthcare providers.

Patient Experience

• Mild discomfort during blood draw similar to standard blood tests.
• Patients may feel relieved knowing their cells are preserved and ready for potentially life-saving treatment.
• No significant pain management is generally required for this process.